Kingsview Wealth Management LLC Increases Stock Holdings in Edwards Lifesciences Corporation $EW

Kingsview Wealth Management LLC raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 67.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,625 shares of the medical research company’s stock after acquiring an additional 17,188 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Edwards Lifesciences were worth $3,315,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. True Wealth Design LLC boosted its stake in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. NewSquare Capital LLC increased its stake in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the period. Hantz Financial Services Inc. lifted its holdings in Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares in the last quarter. Rakuten Securities Inc. boosted its position in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the period. Finally, Steigerwald Gordon & Koch Inc. purchased a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $30,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on EW shares. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. Citigroup restated a “buy” rating and set a $101.00 price target (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. TD Cowen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Friday, January 9th. Finally, Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $96.14.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 24,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. This trade represents a 53.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 79,144 shares of company stock worth $6,685,688 over the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.1%

Edwards Lifesciences stock opened at $85.23 on Thursday. The stock has a market cap of $49.50 billion, a PE ratio of 46.57, a P/E/G ratio of 2.22 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The stock’s fifty day moving average is $82.71 and its two-hundred day moving average is $81.41. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter in the previous year, the company posted $0.59 EPS. The company’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.